AbbVie Inc.

Humira (adalimumab) was first approved by the FDA in 2002. Its original composition-of-matter patent expired in 2016. Had the patent system worked as designed, biosimilar competition would have entered the U.S. market in 2016 or shortly after. Instead, AbbVie spent fifteen years filing 311 additional patents on the drug — covering delivery devices, formulations, concentrations, and manufacturing processes — of which 165 were granted. The effect was a legal minefield that prevented any biosimilar maker from entering the U.S. market without triggering patent litigation. Amgen's Amjevita was the first FDA-approved Humira biosimilar, cleared in September 2016. AbbVie sued Amgen for patent infringement. The lawsuit ended in a confidential pay-to-delay settlement. Amgen agreed not to enter the U.S. market until January 2023 — seven years after FDA approval — in exchange for undisclosed terms. AbbVie reached similar agreements with other biosimilar manufacturers. European regulators, operating under a different patent framework, saw biosimilars enter the market starting in October 2018. Between 2016 and 2023 — the period during which U.S. patients had no alternative — AbbVie raised Humira's price by 60% and collected $114 billion in U.S. revenue from a single drug. The House Oversight and Reform Committee investigated and concluded in 2021 that AbbVie pursued a variety of tactics to increase drug sales while raising prices for Americans, including exploiting the patent system to extend its market monopoly, abusing orphan drug protections to further block competition, and engaging in anticompetitive pricing practices. No criminal charges followed.

• —311 patents filed on Humira; 165 granted — the largest pharmaceutical patent thicket on record for a single drug.
• —First FDA-approved biosimilar (Amjevita, Amgen): September 2016. U.S. market entry: January 2023. Gap: 7 years.
• —European biosimilar market entry: October 2018 — U.S. patients waited 5 additional years after European access.
• —Pay-to-delay settlement with Amgen: terms confidential; Amgen delayed U.S. launch in exchange for undisclosed compensation.
• —AbbVie raised Humira's U.S. list price 60% between 2016 and 2023 despite biosimilar approval pending.
• —$114 billion in U.S. Humira revenue extracted during the 2016–2023 monopoly extension period.
• —House Oversight Committee (2021): found AbbVie exploited the patent system, abused orphan drug protections, and engaged in anticompetitive pricing practices.
• —No criminal charges filed against AbbVie or any executive in connection with the patent thicket.

AbbVie's record of federal enforcement actions spans three separate violations across different drugs and different subsidiaries. Allergan opioid marketing — $2.37 billion (2022): AbbVie acquired Allergan in 2020 for $63 billion. In July 2022, AbbVie agreed to pay up to $2.37 billion to settle U.S. lawsuits alleging that Allergan had illegally marketed opioid analgesics — contributing to the opioid epidemic by aggressively promoting addictive painkillers to physicians. AbbVie denied wrongdoing. Humira nurse ambassador kickback — $24 million (2020): The DOJ found that AbbVie embedded registered nurses in patient practices not to provide clinical care but to build patient loyalty to Humira and discourage prescribers from switching patients to alternatives. The program constituted a kickback scheme in violation of the False Claims Act. AbbVie paid $24 million to resolve the allegations. AbbVie denied wrongdoing. TriCor kickbacks — $25 million (2018): Abbott Laboratories and AbbVie paid $25 million to resolve DOJ allegations of kickback schemes and off-label marketing for TriCor (fenofibrate), a cholesterol drug. AbbVie denied wrongdoing.

• —Three separate federal enforcement actions; three separate AbbVie denials of wrongdoing.
• —$2.37 billion (2022): Allergan opioid marketing settlement — U.S. lawsuits over promotion of opioid analgesics.
• —$24 million (2020): Humira nurse-ambassador kickback scheme — DOJ False Claims Act violation; nurses embedded to protect sales rather than provide care.
• —$25 million (2018): TriCor kickback scheme — off-label marketing and kickbacks for cholesterol drug.
• —Total federal enforcement settlement: $2.42 billion across three actions.
• —No criminal charges against any AbbVie or Allergan executive in any of the three actions.

In June 2021, Senate Finance Committee Chairman Ron Wyden launched an investigation into AbbVie's tax practices after the company's public filings revealed a pattern inconsistent with its claimed U.S. operations. The investigation's findings, released in July 2022, documented the following: AbbVie registered Humira's intellectual property — the patents underlying its best-selling drug, which generated the overwhelming majority of its revenue — in Bermuda and other offshore jurisdictions. Through intercompany royalty arrangements, profits were shifted from the U.S. entity (where the sales occurred) to the offshore IP holding entity (where the intellectual property resided). The result: in 2020, AbbVie simultaneously reported a U.S. pretax loss of $4.5 billion and an overseas pretax profit of $7.9 billion — despite 75% of Humira's global sales occurring in the United States. AbbVie reported only 1% of its Humira-related U.S. income for U.S. tax purposes. The Senate Committee found this arrangement exploited loopholes in the Tax Cuts and Jobs Act of 2017. AbbVie subsequently lobbied against Inflation Reduction Act provisions designed to close those gaps.

• —Senate Finance Committee investigation launched June 2021; report released July 2022 (Washington Post, July 7, 2022).
• —AbbVie registered Humira intellectual property in Bermuda and other offshore jurisdictions.
• —Intercompany royalty structure shifted U.S.-generated profits to offshore IP holding entity.
• —75% of global Humira sales occurred in the United States.
• —1% of Humira-derived income reported for U.S. tax purposes.
• —2020 U.S. pretax loss: -$4.5 billion. 2020 overseas pretax profit: +$7.9 billion (simultaneous).
• —Committee chair Wyden wrote directly to CEO Richard Gonzalez naming the structure.
• —AbbVie lobbied against IRA provisions that would have required greater U.S. tax payment.
• —No criminal charges. No penalty assessed beyond public disclosure.